Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Oxytrol Medicaid Reimbursement Expected In 75% Of States At Launch

Executive Summary

Watson expects almost three-quarters of state Medicaid plans to cover its Oxytrol overactive bladder patch immediately upon launch in May
Advertisement

Related Content

Watson Oxytrol Launch Focus On Heavy Sampling Has Delayed Rx Uptake
Watson Oxytrol Launch Focus On Heavy Sampling Has Delayed Rx Uptake
Pfizer/Pharmacia Clears FTC: Viagra Patent Strategy, HRT Safety Are Factors
Pfizer/Pharmacia Clears FTC: Viagra Patent Strategy, HRT Safety Are Factors
Watson Oxytrol Dry Mouth Profile Gives Overactive Bladder Patch Marketing Edge
Watson Oxytrol Dry Mouth Profile Gives Overactive Bladder Patch Marketing Edge
Watson Oxytrol Launch To Focus On Specialists; CSO To Target Primary Care
Advertisement
UsernamePublicRestriction

Register

PS041535

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel